PhRMA, RDPAC In Joint Effort To Deal With China Corruption Problem
This article was originally published in PharmAsia News
U.S. and international drug-maker groups plan to work directly with China health authorities to help deal with the corruption that has enveloped several foreign companies in a widespread scandal, according to an internal memo.
You may also be interested in...
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.